UBS Group
GEVA

UBS Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

UBS Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,135
Closed -$208K – 9237
2015
Q1 		$208K Sell
2,135
-1,140
-35% -$121K ﹤0.01% 4852
2014
Q4 		$304K Buy
+3,275
New +$258K ﹤0.01% 4644

UBS Group's GEVA Position: Q2 2015 in Review

UBS Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 2,135 shares — an estimated $208K sold.

UBS Group first reported a position in GEVA in Q4 2014 and held it in 2 quarters. The position peaked at $304K in Q4 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • UBS Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • UBS Group sold 2,135 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $208K.
  • UBS Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q4 2014 and held it in 2 quarters.
  • UBS Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $304K in Q4 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on UBS Group's 13F filing for Q2 2015, filed 14 Aug 2015.